Phase 3 clinical trials typically enroll about how many patients?

• A. 1,000-3,000
• B. 100-500
• C. 3,000-6,000
• D. 10,000-20,000

Answer: (A)

Phase III trials are the large, confirmatory studies that test how well a new treatment works in a broad patient population and how it compares to the current standard. To reliably detect a true treatment effect and to observe less common side effects, these trials need enough participants to provide solid statistical power. That balance typically falls in the range of about 1,000 to 3,000 patients. This size supports multicenter participation and diverse patient representation while keeping the study feasible in time and cost. While some trials can be a bit larger or smaller depending on disease rarity, expected effect size, and chosen endpoints, the common expectation is a few thousand participants to robustly establish efficacy and safety. Smaller studies, like 100–500, often don’t have enough power, and very large trials (tens of thousands) are usually reserved for specific circumstances or rare conditions and aren’t the standard for most Phase III programs.